COO
Price
$53.91
Change
-$0.26 (-0.48%)
Updated
Sep 11 closing price
Capitalization
10.25B
82 days until earnings call
Intraday BUY SELL Signals
DXR
Price
$11.40
Change
+$0.35 (+3.17%)
Updated
Sep 11 closing price
Capitalization
66.96M
61 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COO vs DXR

COO vs DXR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COO vs. DXR commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Buy and DXR is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COO($10.2B) has a higher market cap than DXR($67M). COO has higher P/E ratio than DXR: COO (18.52) vs DXR (6.79). DXR YTD gains are higher at: -22.712 vs. COO (-34.224). DXR has less debt than COO: DXR (263K) vs COO (2.46B). COO has higher revenues than DXR: COO (4.23B) vs DXR (8.15M).
COODXRCOO / DXR
Capitalization10.2B67M15,224%
EBITDA890MN/A-
Gain YTD-34.224-22.712151%
P/E Ratio18.526.79273%
Revenue4.23B8.15M51,901%
Total Cash139MN/A-
Total Debt2.46B263K935,361%
FUNDAMENTALS RATINGS
COO vs DXR: Fundamental Ratings
COO
DXR
OUTLOOK RATING
1..100
5083
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
8858
PRICE GROWTH RATING
1..100
6545
P/E GROWTH RATING
1..100
89100
SEASONALITY SCORE
1..100
7523

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COO's Valuation (58) in the Medical Specialties industry is in the same range as DXR (79). This means that COO’s stock grew similarly to DXR’s over the last 12 months.

DXR's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as COO (100). This means that DXR’s stock grew similarly to COO’s over the last 12 months.

DXR's SMR Rating (58) in the Medical Specialties industry is in the same range as COO (88). This means that DXR’s stock grew similarly to COO’s over the last 12 months.

DXR's Price Growth Rating (45) in the Medical Specialties industry is in the same range as COO (65). This means that DXR’s stock grew similarly to COO’s over the last 12 months.

COO's P/E Growth Rating (89) in the Medical Specialties industry is in the same range as DXR (100). This means that COO’s stock grew similarly to DXR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COODXR
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 10 days ago
56%
Bullish Trend 10 days ago
66%
Declines
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 5 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
79%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (COO: $53.91 vs. DXR: $11.40)
Brand notoriety: COO and DXR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: COO: 268% vs. DXR: 849%
Market capitalization -- COO: $10.25B vs. DXR: $66.96M
COO [@Pharmaceuticals: Other] is valued at $10.25B. DXR’s [@Pharmaceuticals: Other] market capitalization is $66.96M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $130.41B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $8.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COO’s FA Score shows that 0 FA rating(s) are green while DXR’s FA Score has 0 green FA rating(s).

  • COO’s FA Score: 0 green, 5 red.
  • DXR’s FA Score: 0 green, 5 red.
According to our system of comparison, DXR is a better buy in the long-term than COO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COO’s TA Score shows that 5 TA indicator(s) are bullish while DXR’s TA Score has 5 bullish TA indicator(s).

  • COO’s TA Score: 5 bullish, 5 bearish.
  • DXR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DXR is a better buy in the short-term than COO.

Price Growth

COO (@Pharmaceuticals: Other) experienced а -22.53% price change this week, while DXR (@Pharmaceuticals: Other) price change was +9.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.51%. For the same industry, the average monthly price growth was -3.46%, and the average quarterly price growth was +12.67%.

Reported Earning Dates

COO is expected to report earnings on Dec 03, 2026.

DXR is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-3.51% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
COO
Daily Signal:
Gain/Loss:
DXR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RPEAX44.910.30
+0.67%
Davis Opportunity A
AGGWX33.380.11
+0.33%
American Century Global Gold R
RYMAX72.77N/A
N/A
Rydex Telecommunications H
PBLAX39.42N/A
N/A
Principal Blue Chip A
KCSIX15.55N/A
N/A
Knights of Columbus Small Cap I

COO and

Correlation & Price change

A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COO
1D Price
Change %
COO100%
-0.48%
BDX - COO
56%
Loosely correlated
+0.81%
A - COO
50%
Loosely correlated
+2.66%
ICUI - COO
47%
Loosely correlated
-0.50%
DHR - COO
46%
Loosely correlated
-0.19%
SYK - COO
44%
Loosely correlated
+2.06%
More

DXR and

Correlation & Price change

A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXR
1D Price
Change %
DXR100%
+3.17%
IART - DXR
33%
Poorly correlated
-0.26%
BWAY - DXR
27%
Poorly correlated
+0.14%
AVTR - DXR
23%
Poorly correlated
-0.47%
COO - DXR
20%
Poorly correlated
-0.48%
SHC - DXR
20%
Poorly correlated
+0.60%
More